Regimen improves OS in diffuse large B-cell lymphoma
Click Here to Manage Email Alerts
The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.
Glofitamab-gxbm (Columvi, Genentech) is a CD20xCD3 T-cell engaging bispecific antibody that targets CD3 on the surface of T cells and CD20 on the surface of B cells.
The agent is able to bring the T cell in close proximity to the B cell, thus activating the release of cancer cell-killing proteins from the T cell, according to researchers.
The FDA previously granted accelerated approval to glofitamab-gxbm for treatment of patients with relapsed or refractory diffuse large B-cell lymphoma who received two or more prior lines of systemic therapy.
Researchers conducted the randomized phase 3 STARGLO study to evaluate the efficacy and safety of gemcitabine plus oxaliplatin (GemOx) plus either glofitamab-gxbm or rituximab (Rituxan; Genentech, Biogen) among patients with diffuse large B-cell lymphoma.
Study participants had received at least one prior line of therapy and were not eligible for autologous stem cell transplant.
The study met its primary endpoint, as patients assigned glofitamab-gxbm plus GemOx achieved longer OS.
The safety profile of the combination appeared consistent with known safety profiles of the individual medicines.
“People with this aggressive lymphoma facing relapse or progression after initial treatment have limited options — particularly those who are ineligible for stem cell transplant,” Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of global product development, said in the release. “Building on Columvi’s established benefits, these data demonstrate the potential of this combination regimen to improve survival outcomes in earlier lines of treatment.”
Data will be presented at a medical meeting.
Read more about
Click Here to Manage Email Alerts